FTM
BECOME A MEMBER
() () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () ()

Tag Archives: PRVCF

  • Home
  •  | 
  • Tag Archives: "PRVCF"

PreveCeutical Files Application to Human Ethics Committee to Acquire Human Tissue for the Final Phase of the Sol-Gel Program

PreveCeutical Files Application to Human Ethics Committee to Acquire Human Tissue for the Final Phase of the Sol-Gel Program
April 15th, 2019, Vancouver, British Columbia: PreveCeutical Medical Inc. (“PreveCeutical”) (CSE: PREV, OTCQB: PRVCF, FSE: 18H), announces the Company’s research team at the University of Queensland has filed an application to a local hospital’s Human Ethics Committee (the “Human Ethics Committee”) to acquire human nasal mucosal tissue (mucosal membrane) for use in the final phase of the cannabinoid-based, soluble gel (“Sol-gel”) drug delivery research and development program (the “Sol-gel Program”).
Read more

PreveCeutical Announces Further Results from its Preliminary Screening of Peptides Derived from Blue Scorpion Venom in a Cell-Based Brain Cancer Model

PreveCeutical Announces Further Results from its Preliminary Screening of Peptides Derived from Blue Scorpion Venom in a Cell-Based Brain Cancer Model
April 10, 2019 PreveCeutical Medical Inc. (the “Company” or“PreveCeutical”) (CSE: PREV, OTCQB: PRVCF, FSE: 18H), is pleased to announce further positive results from the preliminary screening of key peptides from its scorpion venom-derived peptide research and development program (the “Peptide Program”), that is expected to enable the Company to generate Nature IdenticalTM peptide therapeutics intended for therapeuticapplications.
Read more

PreveCeutical Announces Default Judgment Against JCN Capital Corp.

PreveCeutical Announces Default Judgment Against JCN Capital Corp.
PreveCeutical Medical Inc. (the “Company” or “PreveCeutical”) (CSE: PREV, OTCQB: PRVCF, FSE: 18H), announces that it has obtained a default judgement against JCN Capital Corp. (“JCN”) in connection with a Supreme Court of British Columbia action (the “Action”). The Action was brought by PreveCeutical in December 2018, against a group of defendants (the “Defendants”) for fraudulent misrepresentation, breach of contract, conspiracy, unjust enrichment and breach of duty of honest performance in connection with services that the Defendants failed to provide to PreveCeutical, and various consulting agreements and subscription agreements entered into between PreveCeutical and certain of the Defendants (see news release dated January 7, 2019).
Read more

Asterion Welcomes Australian Government Awarding of Major Project Status for its Toowoomba Medicinal Cannabis Project

Asterion Welcomes Australian Government Awarding of Major Project Status for its Toowoomba Medicinal Cannabis Project
April 4th, 2019, Vancouver, British Columbia:  Asterion Cannabis Inc. (P.ASTR) (“Asterion”) and PreveCeutical Medical Inc. (“PreveCeutical”) (CSE: PREV, OTCQB: PRVCF, FSE: 18H), announce today that Asterion’s wholly-owned Australian subsidiary, Asterion Australia Pty Ltd, has been awarded Major Project Status for Asterion’s Toowoomba Medicinal Cannabis Project (the “Toowoomba Project” or the “Facility”) by the Australia Federal Government.
Read more